InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
7
T+90 hit rate
17%
T+90 mean return
-12.0%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Freund John Gordon, Director. Insider active across 3 companies, notably COLLEGIUM PHARMACEUTICAL, INC. Cumulatively, 18 disclosures have been published. Split: 0 buy · 7 sells. Total volume traded: €5.5m. History available since 20 May 2021. The latest transaction was disclosed on 15 May 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations18 total
9,791 shares0Common StockSEC:0001062993-25-009806:0
8,791 shares0Common StockSEC:0001562180-24-005334:0
7,693 shares0Common StockSEC:0001062993-24-010540:0
30,000 shares@ US$20.539910.1% of flowCommon StockSEC:0001562180-23-006298:0
4,866 shares0Common StockSEC:0001562180-23-005109:0
9,792 shares0Common StockSEC:0001062993-23-011817:0
8,324 shares0Common StockSEC:0001562180-22-005236:0
14,035 shares0Common StockSEC:0001062993-22-013302:0
17,990 shares@ US$31.28068.4% of flowCommon StockSEC:0001562180-21-004319
17,990 shares@ US$31.28060.074% mcap9.3% of flowCommon StockSEC:0001562180-21-004319:0
3,848 shares0Common StockSEC:0001562180-21-004257
3,848 shares0Common StockSEC:0001562180-21-004257:0
26,367 shares@ US$30.929713.4% of flowCommon StockSEC:0001562180-21-003880
26,367 shares@ US$30.92970.11% mcap13.4% of flowCommon StockSEC:0001562180-21-003880:0
50,827 shares@ US$32.54090.22% mcap27.2% of flowCommon StockSEC:0001562180-21-003755:0
50,827 shares@ US$32.540927.2% of flowCommon StockSEC:0001562180-21-003755
9,941 shares0Common StockSEC:0001192482-21-000460
9,941 shares0Common StockSEC:0001192482-21-000460:0
18 of 18 declarations
About Freund John Gordon
John Gordon Freund is a Director at Collegium Pharmaceutical, Inc. and SI-BONE, Inc. As a board member, he participates in governance and strategic decision-making. His experience in the pharmaceutical sector is valuable for these companies.
